Ardelyx-Launches-Irritable-Bowel-Syndrome-Treatment-Ibsrela
Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela
April 14, 2022
Pfizer-Recalls-Five-Lots-of-Accupril
Pfizer Recalls Five Lots of Accupril
April 22, 2022
Ardelyx-Launches-Irritable-Bowel-Syndrome-Treatment-Ibsrela
Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela
April 14, 2022
Pfizer-Recalls-Five-Lots-of-Accupril
Pfizer Recalls Five Lots of Accupril
April 22, 2022
Zerbaxa-Now-Indicated-for-Children

April 21, 2022 – Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, in patients of all ages. It was previously approved for this use only in adults.

  • First FDA approved in 2014, Zerbaxa is also indicated to treat adults who have hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
  • Recommended dosing and the duration of treatment are based on factors such as the patient’s age, weight, renal health, and diagnosis.